PepGen

IPO

Better Technology. Better Delivery.

Public · Boston, United States · Founded 2018 · $160.4M raised

Employees
51–200
Founded
2018
Business Model
B2B
Website
pepgen.com
Total Funding
$160.4M
Last Round
$112.5M Series BAug 2021
Rounds
3
Type
Public

About

PepGen is a clinical-stage biotechnology company advancing a new generation of oligonucleotide therapies for neuromuscular and neurological diseases. Leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen addresses the delivery challenges of prior-generation therapies by enabling deep tissue penetration and high uptake in key muscle tissues. The company's lead programs target myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy, with plans to expand into additional indications.

Summary

PepGen is a Healthcare company based in Boston, United States, founded in 2018. It has raised $160.4M in total across 3 rounds, most recently a $112.5M Series B round in Aug 2021. Investors include RA Capital Management, Oxford Science Enterprises and SVB Leerink.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOMay 2022
$122.9M

Sign up to see all 4 rounds

Seed through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

PepGen on Indexed.vc
<a href="https://indexed.vc/companies/pepgen"><img src="https://indexed.vc/api/badge/company/pepgen" alt="PepGen on Indexed.vc" width="260" height="76" /></a>